{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:07:45Z","timestamp":1791245265752,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 5\u201310% of women of reproductive age. It is characterized by chronic anovulation leading to menstrual disorders, and increased infertility. The syndrome can also manifest as hirsutism and acne.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the study<\/jats:title><jats:p>The aim of the study was to compare, over a duration of 6 months, the effects of drospirenone (DRSP) versus chlormadinone acetate (CMA) containing oral contraceptives (OCs) on clinical, hormonal, and metabolic parameters in 120 PCOS women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>120 women with the diagnosis of PCOS according to the Rotterdam 2003 criteria were recruited to the study. All patients were divided to two treatment groups of OCs, containing: 3 mg DRSP\/30 mcg EE (ethinylestradiol) (60 patients) and 2 mg CMA\/30 mcg EE (60 patients). Clinical parameters such as hirsutismus and acne were evaluated. Metabolic parameters such as serum insulin, glucose concentration, homeostatic model assessment of insulin resistance, body mass index, systolic and diastolic blood pressures were also measured. Among hormonal parameters, serum estradiol, luteinizing hormone, follicle-stimulating hormone, prolactin, testosterone, dehydroepiandrosterone sulfate, thyroid-stimulating hormone, and free thyroxine were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The use of both DRSP- or CMA-containing OCs provided similar positive therapeutic effects with regard to clinical, metabolic, and hormonal parameters. Among clinical parameters, like hirsutismus, after 6 months of continuous OC treatment, a statistically significant improvement was observed in both groups: DRSP (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u20090.0001) and CMA OC treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In addition, significant improvement was showed according to acne lesions both after DRSP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and CMA treatments (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Among glucose, insulin levels and HOMA-IR, there were statistically significant higher levels in both groups after DRSP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and CMA OC treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Hormonal parameters such as LH, FSH, prolactin, testosterone and DHEA-S were statistically significant lower in both groups after DRSP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090,002, and<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and CMA OC treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.04,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.002, and<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Further research, however, is needed not only to define optimal duration, and to clarify the effects of treatment on long-term metabolic outcomes, but also to explore different treatment options and possible combined therapies.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s40618-019-01133-3","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:16:04Z","timestamp":1572048964000},"page":"483-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)"],"prefix":"10.1007","volume":"43","author":[{"given":"A.","family":"Podfigurna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Meczekalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Petraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Luisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"issue":"10","key":"1133_CR1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40618-018-0832-1","volume":"41","author":"R Pasquali","year":"2018","unstructured":"Pasquali R, Gambineri A (2018) New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest 41(10):1123\u20131135","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"1133_CR2","first-page":"384","volume":"1","author":"P Sagvekar","year":"2018","unstructured":"Sagvekar P, Dadachanji R, Patil K, Mukherjee S (2018) Pathomechanisms of polycystic ovary syndrome: multidimensional approaches. Front Biosci (Elite Ed) 1(10):384\u2013422","journal-title":"Front Biosci (Elite Ed)"},{"issue":"1","key":"1133_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","unstructured":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41\u201347","journal-title":"Hum Reprod"},{"issue":"4","key":"1133_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.21037\/tp.2017.09.08","volume":"6","author":"M Lause","year":"2017","unstructured":"Lause M, Kamboj A, Fernandez Faith E (2017) Dermatologic manifestations of endocrine disorders. Transl Pediatr 6(4):300\u2013312","journal-title":"Transl Pediatr"},{"issue":"6","key":"1133_CR5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/0002-9378(92)91779-A","volume":"167","author":"E Carmina","year":"1992","unstructured":"Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA (1992) Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 167(6):1807\u20131812","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1133_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/09513590.2018.1427713","volume":"34","author":"A Stapinska-Syniec","year":"2018","unstructured":"Stapinska-Syniec A, Grabowska K, Szpotanska-Sikorska M, Pietrzak B (2018) Depression, sexual satisfaction, and other psychological issues in women with polycystic ovary syndrome. Gynecol Endocrinol 34(7):597\u2013600","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"1133_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/09513590.2015.1009437","volume":"31","author":"A Podfigurna-Stopa","year":"2015","unstructured":"Podfigurna-Stopa A, Luisi S, Regini C, Katulski K, Centini G, Meczekalski B, Petraglia F (2015) Mood disorders and quality of life in polycystic ovary syndrome. Gynecol Endocrinol 31(6):431\u2013434","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"1133_CR8","first-page":"148","volume":"18","author":"K Katulski","year":"2012","unstructured":"Katulski K, Rojewska P, Meczekalski B (2012) The influence of polycystic ovary syndrome on patient quality of life. Arch Perinat Med 18(3):148\u2013152","journal-title":"Arch Perinat Med"},{"issue":"8","key":"1133_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1007\/s10597-017-0188-6","volume":"54","author":"M Mirghafourvand","year":"2018","unstructured":"Mirghafourvand M, Charandabi SM, Lak TB, Aliasghari F (2018) Predictors of depression in Iranian women with polycystic ovarian syndrome. Commun Ment Health J 54(8):1274\u20131283","journal-title":"Commun Ment Health J"},{"key":"1133_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.psyneuen.2017.08.007","volume":"85","author":"CE Cesta","year":"2017","unstructured":"Cesta CE, Kuja-Halkola R, Lehto K, Iliadou AN, Land\u00e9n M (2017) Polycystic ovary syndrome, personality, and depression: a twin study. Psychoneuroendocrinology 85:63\u201368","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"1133_CR11","first-page":"357","volume":"32","author":"LL Yanes Cardozo","year":"2017","unstructured":"Yanes Cardozo LL, Romero DG, Reckelhoff JF (2017) Cardiometabolic features of polycystic ovary syndrome: role of androgens. Physiology (Bethesda) 32(5):357\u2013366","journal-title":"Physiology (Bethesda)"},{"issue":"9371","key":"1133_CR12","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0140-6736(03)13409-5","volume":"361","author":"P Hardiman","year":"2003","unstructured":"Hardiman P, Pillay O, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361(9371):1810\u20131812","journal-title":"Lancet"},{"issue":"5","key":"1133_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-018-0953-6","volume":"42","author":"WY Cai","year":"2019","unstructured":"Cai WY, Gao JS, Luo X, Ma HL, Ge H, Liu N, Xia Q, Wang Y, Han BW, Wu XK (2019) Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial. J Endocrinol Invest 42(5):549\u2013555","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40618-018-0949-2","volume":"42","author":"L Mu","year":"2019","unstructured":"Mu L, Li R, Lai Y, Zhao Y, Qiao J (2019) Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome. J Endocrinol Invest 42(5):541\u2013548","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1133_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s40618-018-0902-4","volume":"41","author":"L Zhang","year":"2018","unstructured":"Zhang L, Fang X, Li L, Liu R, Zhang C, Liu H, Tan M, Yang G (2018) The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. J Endocrinol Invest 41(12):1401\u20131407","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/humupd\/dmu012","volume":"20","author":"JA Barry","year":"2014","unstructured":"Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748\u2013758","journal-title":"Hum Reprod Update"},{"issue":"2","key":"1133_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1471-0528.2008.02041.x","volume":"116","author":"W Atiomo","year":"2009","unstructured":"Atiomo W, Khalid S, Parameshweran S, Houda M, Layfield R (2009) Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review. BJOG 116(2):137\u2013143","journal-title":"BJOG"},{"key":"1133_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cca.2017.06.009","volume":"471","author":"SE Karakas","year":"2017","unstructured":"Karakas SE (2017) New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta 471:248\u2013253","journal-title":"Clin Chim Acta"},{"issue":"7","key":"1133_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.29252\/ijrm.15.7.423","volume":"15","author":"B Namavar Jahromi","year":"2017","unstructured":"Namavar Jahromi B, Dabaghmanesh MH, Parsanezhad ME, Fatehpoor F (2017) Association of leptin and insulin resistance in PCOS: a case-controlled study. Int J Reprod Biomed (Yazd) 15(7):423\u2013428","journal-title":"Int J Reprod Biomed (Yazd)"},{"issue":"3","key":"1133_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1515\/hmbci-2016-0047","volume":"29","author":"E Alexiou","year":"2017","unstructured":"Alexiou E, Hatziagelaki E, Pergialiotis V, Chrelias C, Kassanos D, Siristatidis C, Kyrkou G, Kreatsa M, Trakakis E (2017) Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index. Horm Mol Biol Clin Investig 29(3):105\u2013111","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"2","key":"1133_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1358863X16682107","volume":"22","author":"SS Patel","year":"2017","unstructured":"Patel SS, Truong U, King M, Ferland A, Moreau KL, Dorosz J, Hokanson JE, Wang H, Kinney GL, Maahs DM, Eckel RH, Nadeau KJ, Cree-Green M (2017) Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers. Vasc Med 22(2):85\u201395","journal-title":"Vasc Med"},{"issue":"3","key":"1133_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/IJWH.S11304","volume":"8","author":"A Badawy","year":"2011","unstructured":"Badawy A, Elnashar A (2011) Treatment options for polycystic ovary syndrome. Int J Womens Health 8(3):25\u201335","journal-title":"Int J Womens Health"},{"issue":"3","key":"1133_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1210\/jc.2014-3196","volume":"100","author":"BO Yildiz","year":"2015","unstructured":"Yildiz BO (2015) Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab 100(3):794\u2013802","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1133_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3109\/09513590.2015.1006187","volume":"31","author":"R Yildizhan","year":"2015","unstructured":"Yildizhan R, Gokce AI, Yildizhan B, Cim N (2015) Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol 31(5):396\u2013400","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"1133_CR25","first-page":"175","volume":"39","author":"N Helvaci","year":"2014","unstructured":"Helvaci N, Yildiz BO (2014) Oral contraceptives in polycystic ovary syndrome. Minerva Endocrinol 39(3):175\u2013187","journal-title":"Minerva Endocrinol"},{"issue":"5","key":"1133_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0010-7824(03)00027-1","volume":"67","author":"DM Breitkopf","year":"2003","unstructured":"Breitkopf DM, Rosen MP, Young SL, Nagamani M (2003) Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 67(5):349\u2013353","journal-title":"Contraception"},{"issue":"1","key":"1133_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/humupd\/dmp024","volume":"16","author":"BO Yildiz","year":"2010","unstructured":"Yildiz BO, Bolour S, Woods K, Moore A, Azziz R (2010) Visually scoring hirsutism. Hum Reprod Update 16(1):51\u201364","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1133_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12958-017-0313-y","volume":"15","author":"SF de Medeiros","year":"2017","unstructured":"de Medeiros SF (2017) Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol 15(1):93","journal-title":"Reprod Biol Endocrinol"},{"key":"1133_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx039","author":"M Luque-Ram\u00edrez","year":"2017","unstructured":"Luque-Ram\u00edrez M, Nattero-Ch\u00e1vez L, Ortiz Flores AE, Escobar-Morreale HF (2017) Combined oral contraceptives and\/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. https:\/\/doi.org\/10.1093\/humupd\/dmx039 (Epub ahead of print)","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1133_CR30","first-page":"109","volume":"14","author":"D Macut","year":"2015","unstructured":"Macut D, Bo\u017ei\u0107 Anti\u0107 I, Nestorov J, Topalovi\u0107 V, Bjeki\u0107 Macut J, Panidis D, Kastratovi\u0107 Kotlica B, Papadakis E, Mati\u0107 G, Vojnovi\u0107 Milutinovi\u0107 D (2015) The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. Hormones (Athens) 14(1):109\u2013117","journal-title":"Hormones (Athens)"},{"issue":"3","key":"1133_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jog.12543","volume":"41","author":"S Leelaphiwat","year":"2015","unstructured":"Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, Weerakiet S (2015) Comparison of desogestrel\/ethinyl estradiol plus spironolactone versus cyproterone acetate\/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res 41(3):402\u2013410","journal-title":"J Obstet Gynaecol Res"},{"issue":"7","key":"1133_CR32","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1210\/jc.2014-1135","volume":"99","author":"D Glintborg","year":"2014","unstructured":"Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M (2014) Body composition is improved during 12\u00a0months\u2019 treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99(7):2584\u20132591","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1133_CR33","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.fertnstert.2014.02.039","volume":"101","author":"MG Mes-Krowinkel","year":"2014","unstructured":"Mes-Krowinkel MG, Louwers YV, Mulders AG, de Jong FH, Fauser BC, Laven JS (2014) Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 101(6):1757\u20131765","journal-title":"Fertil Steril"},{"issue":"2","key":"1133_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00404-014-3217-5","volume":"290","author":"K Kahraman","year":"2014","unstructured":"Kahraman K, S\u00fck\u00fcr YE, Atabeko\u011flu CS, Ate\u015f C, Ta\u015fk\u0131n S, Cetinkaya SE, Tolunay HE, Ozmen B, S\u00f6nmezer M, Berker B (2014) Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 290(2):321\u2013328","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"1133_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/09513590.2014.975688","volume":"30","author":"C Di Carlo","year":"2013","unstructured":"Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Nappi C (2013) Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol 30(12):925\u2013928","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1133_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/09513590.2012.743007","volume":"29","author":"ST Bird","year":"2013","unstructured":"Bird ST, Hartzema AG, Etminan M, Brophy JM, Delaney JA (2013) Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecol Endocrinol 29(4):365\u2013369","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1133_CR37","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","volume":"98","author":"SM Bhattacharya","year":"2012","unstructured":"Bhattacharya SM, Jha A (2012) Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 98(4):1053\u20131059","journal-title":"Fertil Steril"},{"issue":"3","key":"1133_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.contraception.2012.07.005","volume":"87","author":"K Aydin","year":"2018","unstructured":"Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO (2018) Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception 87(3):358\u2013362","journal-title":"Contraception"},{"issue":"2","key":"1133_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijgo.2015.06.065","volume":"132","author":"SM Bhattacharya","year":"2016","unstructured":"Bhattacharya SM, Jha A, DasMukhopadhyay L (2016) Comparison of two contraceptive pills containing drospirenone and 20\u00a0\u03bcg or 30\u00a0\u03bcg ethinyl estradiol for polycystic ovary syndrome. Int J Gynaecol Obstet 132(2):210\u2013213","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"1133_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40834-018-0058-9","volume":"10","author":"U Jaisamrarn","year":"2018","unstructured":"Jaisamrarn U, Santibenchakul S (2018) A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 10(3):5","journal-title":"Contracept Reprod Med"},{"issue":"5","key":"1133_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0010-7824(03)00006-4","volume":"67","author":"I Wiegratz","year":"2003","unstructured":"Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H (2003) Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 67(5):361\u2013366","journal-title":"Contraception"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T20:07:49Z","timestamp":1721938069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01133-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Research have been approved by the appropriate institutional research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent written voluntary consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}